Sexual Health - Libido - Melanocortin

Buy PT-141 Bremelanotide NYC

Cyclic Lactam Melanocortin Analog | Per Vial

From $26.00 / vial

4.9 / 5.0 - 312 reviews

PT-141 Bremelanotide 5mg VialPrice per vial

$26.00

PT-141 Bremelanotide 10mg VialPrice per vial

$32.00

PT-141 5-Vial Pack (5mg each)Bundle savings per pack

$117.00

Your Selection

Order Total$0.00

The sexual wellness peptide: acts centrally on melanocortin receptors to enhance arousal and desire independent of hormonal levels or vascular effects

PT-141, also known as Bremelanotide, is a synthetic cyclic heptapeptide derived from Melanotan II. Unlike PDE5 inhibitors such as Viagra, PT-141 acts directly on the central nervous system by binding to melanocortin receptors (MC3R and MC4R) in the hypothalamus to initiate sexual arousal. This central mechanism makes it effective for both men and women regardless of hormonal status or vascular health, and it does not affect blood pressure. PT-141 was FDA-approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women.

Central nervous system action via MC3R/MC4R receptors - enhances arousal without cardiovascular effects
Effective for both men and women regardless of hormonal levels or vascular health status
FDA-approved (Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women

Delivery

Fast Tracked Priority

Sourcing

USA Genuine Products

Support

Friendly Customer Care

Back to Peptides

Central Arousal: How PT-141 Differs From Traditional Options

PT-141 is fundamentally different from PDE5 inhibitors like sildenafil or tadalafil. Where those compounds work peripherally by relaxing vascular smooth muscle to increase blood flow, PT-141 works centrally - acting on the hypothalamus to directly trigger the neural pathways that initiate sexual arousal and desire. This means it addresses low libido at its neurological root, not just the physical response, and is therefore effective even when libido is the primary issue rather than vascular function.

Clinical trials for Vyleesi demonstrated statistically significant improvements in sexual desire and reductions in distress related to low sexual desire compared to placebo in premenopausal women with HSDD. Male research has shown similar appetite and arousal-initiating effects, with spontaneous erections reported in studies as early as 2000.

Key Benefits

01Central CNS action on MC3R/MC4R: addresses low libido at its neurological root
02Effective for both men and women - the only peptide with clinical data in both sexes for sexual health
03Does not affect blood pressure or require sexual stimulation to initiate arousal response
04FDA-approved (Vyleesi) for HSDD - the most rigorously clinically validated peptide for sexual health
05Rapid onset: effects typically begin within 45 minutes and last 6-12 hours

Product Specifications

Peptide Name	PT-141 (Bremelanotide)
Sequence	Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Molecular Weight	1025.2 g/mol
Form	Lyophilized powder for reconstitution
Purity	> 99% (HPLC verified)
Storage	Refrigerate at 2-8 degrees C; avoid light
Price	From $26.00 per vial

Results Timeline

30-45 Minutes

Initial effects begin as melanocortin receptors activate. Most users report a warming sensation and heightened arousal awareness within the first hour of administration.

1-6 Hours

Peak arousal window. Effects persist for 6-12 hours, providing a sustained window that does not require precise timing relative to activity.

With Protocol

Consistent use as part of a sexual wellness protocol can help re-establish healthy desire patterns and improve relationship satisfaction over time.

Step 1: Subcutaneous Administration

PT-141 is administered subcutaneously, typically in the abdominal region. It is rapidly absorbed into systemic circulation and crosses the blood-brain barrier efficiently due to its cyclic structure and lipophilic properties. Unlike vascular agents, its destination is the hypothalamus, not peripheral vasculature.

Step 2: Hypothalamic MC3R/MC4R Binding

PT-141 binds to melanocortin receptor subtypes 3 and 4 in the hypothalamus and limbic system. These receptors are directly involved in regulating sexual motivation, arousal, and desire. Activation of MC4R in particular initiates a downstream signaling cascade that results in heightened sexual motivation independent of testosterone, estrogen, or vascular status.

Step 3: Neural Arousal Pathway Activation

MC receptor activation stimulates dopaminergic pathways in the mesolimbic system, increasing dopamine signaling associated with motivation and reward. This central arousal mechanism produces genuine desire rather than merely a peripheral physiological response, making PT-141 uniquely effective for individuals whose primary challenge is low libido rather than physical performance.

Step 4: Sustained Effect Window

Unlike PDE5 inhibitors that require precise 30-60 minute timing before activity, PT-141's central mechanism provides a sustained 6-12 hour arousal window from a single dose. This extended window and its independence from sexual stimulation for initial activation make it particularly suited for use in wellness protocols addressing chronic low desire.

Who Benefits Most from PT-141?

PT-141 is suited for adults of any sex experiencing reduced sexual desire, hypoactive sexual desire disorder (HSDD), or those seeking to enhance sexual wellness as part of a comprehensive longevity and health protocol. Its central mechanism makes it uniquely effective for individuals where low libido is the primary concern - not vascular or hormonal dysfunction - and for women, where traditional sexual health options have historically been limited.

Ideal Candidates

+Premenopausal or postmenopausal women with reduced sexual desire or HSDD diagnosis
+Men experiencing low libido or desire-related challenges not fully addressed by PDE5 inhibitors alone
+Adults incorporating sexual wellness into a broader longevity and hormone optimization protocol
+Those seeking an alternative to hormonal treatments for desire-related sexual dysfunction

Use With Caution

-Individuals with cardiovascular disease or uncontrolled hypertension - monitor blood pressure
-Those with a history of melanoma or atypical nevi - melanocortin stimulation may affect pigmentation
-Pregnant or breastfeeding individuals

Consult a licensed healthcare provider before beginning any peptide protocol. See Important Safety Information below.

PT-141 and Viagra (sildenafil) work through completely different mechanisms. Sildenafil is a PDE5 inhibitor that relaxes vascular smooth muscle to increase blood flow to genital tissue - it addresses the physical response but not desire. PT-141 works centrally in the brain, activating melanocortin receptors in the hypothalamus to initiate genuine arousal and desire. It also works for women, is not dependent on sexual stimulation to initiate its effect, and does not significantly affect blood pressure.

Most users begin to notice effects within 30 to 45 minutes of administration. Peak effects typically occur between 1 and 3 hours and the arousal window lasts 6 to 12 hours from a single dose. The extended window is one of PT-141's significant practical advantages - unlike PDE5 inhibitors, precise timing is not required.

Yes. PT-141 (Bremelanotide) was FDA-approved in June 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the first non-hormonal, centrally-acting treatment for female sexual dysfunction to receive FDA approval. Research use of the research compound PT-141 is separate from the approved pharmaceutical product.

The most commonly reported side effects in clinical trials were nausea (reported in approximately 40% of Vyleesi subjects), flushing, and injection site reactions. Nausea typically occurred within one hour of dosing and resolved within 2 hours. Taking an anti-nausea medication 30 minutes before dosing can significantly reduce this effect. Transient increases in blood pressure (usually resolving within 12 hours) were also reported and should be monitored in individuals with cardiovascular risk factors.